These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37528288)
1. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer. Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288 [TBL] [Abstract][Full Text] [Related]
2. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646 [TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study. Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015 [TBL] [Abstract][Full Text] [Related]
4. Rate of Pathogenic Germline Variants in Patients With Lung Cancer. Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258 [TBL] [Abstract][Full Text] [Related]
5. Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. Sabol RA; Ledet EM; Jaeger E; Hatton W; Moses M; Lankford A; Zaheria A; Barata P; Layton JL; Lewis BE; Sartor O Prostate; 2021 May; 81(7):427-432. PubMed ID: 33760238 [TBL] [Abstract][Full Text] [Related]
6. Prevalence and spectrum of cancer predisposition germline mutations in young patients with the common late-onset cancers. Hao S; Zhao X; Fan Y; Liu Z; Zhang X; Li W; Yuan H; Zhang J; Zhang Y; Ma T; Tao H Cancer Med; 2023 Sep; 12(17):18394-18404. PubMed ID: 37610374 [TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial. Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391 [TBL] [Abstract][Full Text] [Related]
9. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585 [TBL] [Abstract][Full Text] [Related]
10. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661 [TBL] [Abstract][Full Text] [Related]
12. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242 [TBL] [Abstract][Full Text] [Related]
14. High-risk pathogenic germline variants in blood relatives of BRCA1/2 negative probands. Yoshida R; Kaneyasu T; Ueki A; Yamauchi H; Ohsumi S; Ohno S; Aoki D; Baba S; Kawano J; Matsumoto N; Nagasaki M; Ueno T; Inari H; Kobayashi Y; Takei J; Gotoh O; Nishi M; Okamura M; Kaneko K; Okawa M; Suzuki M; Amino S; Inuzuka M; Noda T; Mori S; Nakamura S Breast Cancer; 2024 Jul; ():. PubMed ID: 39003386 [TBL] [Abstract][Full Text] [Related]
15. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755 [TBL] [Abstract][Full Text] [Related]